|
$25 Million Verdict Awarded to Former Accutane User
In yet another major verdict against the pharmaceutical company Hoffmann-La Roche, a New Jersey jury unanimously ordered the company to pay $25.16 million in damages to a former user of its Accutane drug. More...
New Jersey Jury Awards $12.9 Million to Three Patients Whose
Use of Roche Acne Medication Accutane Found to Cause Severe Bowel Illness
In another major courtroom verdict linking powerful acne medication Accutane with
long-term inflammatory bowel disease (IBD), an eight-person jury in Atlantic City
has found that pharmaceutical maker Hoffman-La Roche failed to provide adequate
warning of the possible condition to three patients who began taking the drug as
teenagers and shortly thereafter developed severe forms of IBD. The jury awarded
compensatory damages of $12.89 million to be apportioned among the three individuals,
now aged in their mid-to-late 20s.More...
Third Straight Plaintiff's Verdict, and
Largest to Date, in Accutane Litigation
On Tuesday, a jury in Atlantic City, NJ,
ordered the pharmaceutical manufacturer
Roche to pay plaintiff Kamie Kendall
$10,578,500.00, for injuries caused by
its drug Accutane.
More...
Jury Finds Transmission Defect in
Chrysler Vehicle Caused Death of
Infant
April 9, 2008, Chalmette, Louisiana -- A Louisiana-state jury yesterday found DaimlerChrysler
liable for the death of infant Collin Guillot and injuries to his parents Juli and
August Guillot and their then 3 year old daughter Madison. The jury returned a unanimous
verdict of $5,080,000 in compensatory damages. More...
Jury awards $7 million in Florida
Accutane case<
After two days of deliberating, the jury on Thursday found Accutane maker Hoffman-La
Roche Inc. responsible for... More...
Permax Removed from Market
On March 29, 2007, the FDA announced that manufacturers of pergolide drug products,
which are used to treat Parkinson’s disease, will voluntarily remove these
drugs from the market...
More...
Breaking News
|
Roche Pulls Accutane Off Market After Jury Verdicts
Roche Holding AG, the world's biggest maker of cancer drugs, is pulling its Accutane
acne medicine from the U.S. market after juries awarded at least $33 million in
damages to users who blamed the drug for bowel disease. More...
Reglan Alert
Recent studies have linked long-term use of the drug REGLAN to the development of
tardive dyskinsesia (TD). TD is a serious and often permanent neurological disorder
characterized by involuntary, repetitive movements in the face and extremities.
More...
NuvaRing®
The NuvaRing® is a once-a-month combined contraceptive vaginal ring, which was
approved for use the United States in October. However, since the NuvaRing®
hit the market it has been the subject of many lawsuits related to blood clots and
has also been blamed for 12 deaths nationwide. More...
Auto Accident? Remember 1-2-3-4-5
If you have the misfortune of being involved in an auto accident, you should remember
five very important points, and keep this valuable Accident Form in your car. Read
on to learn the five points and to print you free form. More...
18-Wheelers or Tractor-Trailers
Tractor-trailers also known as 18-wheelers or “semis” account for thousands
of accidents in the United States every year...
More...
Contact Us Today!
Benzene Alert!
Workers exposed to high levels of benzene are at the greatest risk of suffering
its long-term harmful effects. More....
Free Form
Guidant Initiates Worldwide Physician Communications
Guidant said it is voluntarily advising physicians about important safety information
regarding certain devices. Guidant apprised FDA of this action, and FDA may classify
this action as a recall. More....
FDA considers extending deadline
The tens of thousands of Americans who take Accutane to treat their severe
acne may gain additional time to register with a program designed to limit use of
the birth defect-causing drug by pregnant women,
More....
What is Mesothelioma?
Mesothelioma is caused by exposure to asbestos and symptoms may not appear for as
long as 20 to 40 years after exposure.
More....
|
|
